Long-term antimullerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.

ABSTRACT:

Objective

To compare antimüllerian hormone (AMH) patterns by cancer status and treatment exposures across 6 years after incident breast cancer using administrative data.

Design

In a cross-sectional design, AMH levels in patients who developed incident breast cancer between ages 15-39 years during 2005-2019 were matched 1:10 to levels in females without cancer in the OptumLabs Data Warehouse. Modeled AMH patterns were compared among cyclophosphamide-based chemotherapy, non-cyclophosphamide-based chemotherapy, no chemotherapy, and no breast cancer groups.

Setting

Commercially insured females in the United States.

Patient(s)

Females with and without breast cancer.

Exposure(s)

Breast cancer, cyclophosphamide- and non-cyclophosphamide-based chemotherapy.

M

SUBMITTER: Zhou B 

PROVIDER: S-EPMC9081208 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature